Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Claire N. Harrison, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Haifa Kathrin Al-Ali, MD, Heinz Gisslinger, MD, Laurent Knoops, MD PhD, Francisco Cervantes, Mark M. Jones, MD, Kang Sun, PhD, Laurence Descamps, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Tiziano Barbui, MD

Blood (2015) 126 (23): 59.

https://doi.org/10.1182/blood.V126.23.59.59

Published: 2015

Journal Articles

Mathematical Modeling of Patient-Level Hemoglobin Delineates Ruxolitinib’s Complex Mechanism of Action and Quantifies Anemia Risk

Celine Sarr, PhD, Shweta Urva, PhD, Jerry Nedelman, PhD, William Sallas, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Dany Habr, MD, Renaud Capdeville, MD

Blood (2014) 124 (21): 3228.

https://doi.org/10.1182/blood.V124.21.3228.3228

Published: 2014

Journal Articles

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

Simon Durrant, MD, Maya Koren-Michowitz, MD, David Lavie, Joaquin Martinez-Lopez, MD PhD, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Viktoriya Stalbovskaya, PhD, Edric Atienza, MSHS, Dana Iommazzo, Prashanth Gopalakrishna, MBBS, MRCS, Heinz Gisslinger, MD

Blood (2014) 124 (21): 710.

https://doi.org/10.1182/blood.V124.21.710.710

Published: 2014

Journal Articles

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

Paola Guglielmelli, PhD MD, Giada Rotunno, BiSci, Costanza Bogani, PhD, Carmela Mannarelli, MSc, Matthew Squires, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1853.

https://doi.org/10.1182/blood.V124.21.1853.1853

Published: 2014

Journal Articles

A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Baseline Platelet Counts from 50 × 10 9 /L to 99 × 10 9 /L (The EXPAND Study)

Peter te Boekhorst, MD PhD, Claire N. Harrison, DM, FRCP, FRCPath, Heinz Gisslinger, MD PhD, Dietger Niederwieser, MD, Viktoriya Stalbovskaya, PhD, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 1841.

https://doi.org/10.1182/blood.V124.21.1841.1841

Published: 2014

Journal Articles

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)

Haifa Kathrin Al-Ali, MD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Julian Perez Ronco, MD MBA, Lynda M Foltz, MD FRCP

Blood (2014) 124 (21): 4583.

https://doi.org/10.1182/blood.V124.21.4583.4583

Published: 2014

Journal Articles

The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT)

Matthew Squires, PhD, Claire N Harrison, DM, FRCP, FRCPath, Giovanni Barosi, MD, Alessandro M Vannucchi, MD, Tiziano Barbui, MD, Heinz Gisslinger, Francesco Passamonti, MD, Haifa Kathrin Al-Ali, MD, Jean-Jacques Kiladjian, MD, PhD, Mahtab T. Marker, PhD, Estella T. Mendelson, BSRN, MBA, Viktoriya Stalbovskaya, PhD, Francisco Cervantes, MD, PhD, Laurent Knoops, MD, PhD

Blood (2013) 122 (21): 4070.

https://doi.org/10.1182/blood.V122.21.4070.4070

Published: 2013

Journal Articles

A Pooled Overall Survival Analysis of The COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib For The Treatment of Myelofibrosis

Alessandro M. Vannucchi, MD, Kantarjian Hagop, Jean-Jacques Kiladjian, MD, PhD, Jason Gotlib, MD, MS, Francisco Cervantes, MD, PhD, Ruben A. Mesa, MD, Giovanni Barosi, MD, Nicholas Sarlis, Wei Peng, PhD, Victor A. Sandor, MD, CM, Andres Sirulnik, MD, PhD, Abdel Hmissi, Viktoriya Stalbovskaya, PhD, Vikas Gupta, MD, FRCP, FRCPath, Claire N Harrison, DM, FRCP, FRCPath, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 2820.

https://doi.org/10.1182/blood.V122.21.2820.2820

Published: 2013

Journal Articles

Impact Of Prognostically Detrimental Mutations ( ASXL1, EZH2, SRSF2, IDH1/2 ) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II

Paola Guglielmelli, PhD MD, Flavia Biamonte, BiSci, PhD, Lisa Pieri, MD PhD, Giada Rotunno, BiSci, Chiara Paoli, BiSci, Rajmonda Fjerza, MD, Enrico Tagliafico, MD PhD, Rossella Manfredini, PhD, Valentina Artusi, MSc, Elena Tenedini, PhD, Lucia Artuso, PhD, Isabella Bernardis, Viktoriya Stalbovskaya, PhD, Matthew Squires, PhD, Claire N Harrison, DM, FRCP, FRCPath, Alessandro M Vannucchi, MD

Blood (2013) 122 (21): 107.

https://doi.org/10.1182/blood.V122.21.107.107

Published: 2013

Journal Articles

Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 × 10 9 /L and 99 × 10 9 /L

Claire N Harrison, DM FRCP FRCPath, Heinz Gisslinger, MD, Carole B. Miller, MD, Jean-Jacques Kiladjian, MD, PhD, Edric Atienza, MSHS, Viktoriya Stalbovskaya, PhD, Andres Sirulnik, MD, PhD, Haifa Kathrin Al-Ali, MD, Giovanni Barosi, MD, Mary Frances McMullin, MD, Srdan Verstovsek, MD, PhD, Alessandro M. Vannucchi, MD

Blood (2012) 120 (21): 177.

https://doi.org/10.1182/blood.V120.21.177.177

Published: 2012

Journal Articles

The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Mary Frances McMullin, MD, Claire N Harrison, DM FRCP FRCPath, Dietger Niederwieser, Hilde Demuynck, Nadja Jakel, Andres Sirulnik, MD, PhD, Mari McQuity, RN, MPH, Viktoriya Stalbovskaya, PhD, Christian Recher, MD, Koen Theunissen, MD, Heinz Gisslinger, MD, Jean-Jacques Kiladjian, MD, PhD, Haifa-Kathrin Al- Ali

Blood (2012) 120 (21): 2838.

https://doi.org/10.1182/blood.V120.21.2838.2838

Published: 2012

Journal Articles

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Francisco Cervantes, MD, Jean-Jacques Kiladjian, MD, PhD, Dietger Niederwieser, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Mari McQuity, RN, MPH, Deborah S. Hunter, PhD, Richard S. Levy, MD, Francesco Passamonti, MD, Tiziano Barbui, MD, Giovanni Barosi, MD, Heinz Gisslinger, MD, Alessandro M. Vannucchi, MD, Laurent Knoops, MD, PhD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 801.

https://doi.org/10.1182/blood.V120.21.801.801

Published: 2012

Journal Articles

Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT)

Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Haifa Kathrin Al-Ali, MD, Giovanni Barosi, MD, Claire N Harrison, DM FRCP FRCPath, Andres Sirulnik, MD, PhD, Viktoriya Stalbovskaya, PhD, Matthew Squires, PhD, Timothy Burn, PhD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, Tiziano Barbui, MD, Heinz Gisslinger, MD, Jean-Jacques Kiladjian, MD, PhD

Blood (2012) 120 (21): 802.

https://doi.org/10.1182/blood.V120.21.802.802

Published: 2012

NARROW

Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results

Mathematical Modeling of Patient-Level Hemoglobin Delineates Ruxolitinib’s Complex Mechanism of Action and Quantifies Anemia Risk

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis

A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Baseline Platelet Counts from 50 × 10 9 /L to 99 × 10 9 /L (The EXPAND Study)

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)

The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT)

A Pooled Overall Survival Analysis of The COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib For The Treatment of Myelofibrosis

Impact Of Prognostically Detrimental Mutations ( ASXL1, EZH2, SRSF2, IDH1/2 ) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II

Expand: a Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis and Baseline Platelet Counts Between 50 × 10 9 /L and 99 × 10 9 /L

The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only